CLDI calidibio.com Final Profit

Corporate emblem and logo of calidibio.com (CLDI)

Calidi Biotherapeutics (CLDI) develops stem cell-based platforms, ensuring clinic dependence on unique patents and guaranteeing high margins. The company's core operating profit reflects its business development dynamics, where -0.02 represents the latest metric reading. However, high scientific uncertainty and the competition for investment in the US create serious challenges for long-term growth.

CLDI (Calidi Bio) Net Profit history from 02/21/2024 to 10/29/2026

Analytical breakdowns and data insights for company calidibio.com (CLDI)

- stock value and consensus price forecast:
Market Price Calidi Biotherapeutics, Inc.|CLDI - Price Target Chart
- market capitalization data:
Market Value Calidi Biotherapeutics|CLDI - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Calidi Biotherapeutics|CLDI - Book Capitalization|Market Cap to Net Assets Ratio calidibio.com|CLDI - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Calidi Biotherapeutics|CLDI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Calidi Biotherapeutics, Inc.|CLDI - Company Aggregate Debts|Debts to Book Value Calidi Biotherapeutics|CLDI - Company Long-Term Debts|Company Current Liabilities Calidi Biotherapeutics|Quick Ratio calidibio.com
- net income and valuation multiples indicators:
CLDI - Company Net Income
Fundamental valuation:CLDI Calidi Bio
Manufactured product of Calidi Biotherapeutics Inc.

When analyzing the issuer's financial stability and net income volatility, investors assess the capital's ability to withstand a flight from risky assets by monitoring daily profit deviations. The bottom-line profit dynamics of Calidi Biotherapeutics (CLDI) reflect the efficiency of developing allogeneic cell therapies, where cash flow stability correlates directly with the successful implementation of innovative oncology platforms.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Income sellaslifesciences.com SLS|Net Profit ACTU (Actuate Therapeutics)|Net Profit Citius Oncology Inc. CTOR|HURA - Company Net Income|TARA: Company Net Income|FATE: Net Profit|WHWK - Net Financial Result|TCRX (TScan Therapeutics Inc) - Net Profit|Company Profit CSBR (Champions Oncology Corp)|Net Profit XBIT|Net Financial Result cel-sci.com|OS Therapies Incorporated - Net Income|Final Profit RADX|Artiva - Net Profit|ANL: Company Net Income|VERU: Net Profit|TPST - Net Financial Result|Company Net Income Xilio Therapeutics Inc|Company Net Income Enochian BioSciences RENB|Net Income MURA (Mural Oncology plc)|Profit After Payment of Taxes KAPA|Net Profit OKUR (OnKure Therapeutics)|Final Profit GDTC|Curis Corp - Net Profit|Company Net Income Apollomics, Inc.|Tharimmune (THAR) - Company Net Income|Advanced Biomed - Final Profit|GNPX (Genprex, Inc) - Net Profit|Net Profit Sunshine Biopharma Inc.|Company Net Income Xenetic Biosciences (XBIO)|SLRX: Profit After Tax|Net Profit PPBT (Purple Biotech Ltd.)|American Oncology Network Inc (AONC) - Company Net Income|BGNE: Net Income|CKPT - Net Profit|ELEV (Elevation Oncology, Inc.) - Net Income|ICAD: Profit After Payment of Taxes|IKNA (Ikena Oncology Inc.) - Net Profit|Notable Labs Ltd (NTBL) - Net Financial Result|Net Profit VIRX|Net Income MorphoSys Corporation MOR|Company Net Income NAYA Biosciences NAYA|Net Financial Result ascentage.com (AAPGV)